Evidence map›Paper›PMID 29453336›Full record

ArticleScientific reports2018

Alternative splicing of ALCAM enables tunable regulation of cell-cell adhesion through differential proteolysis.

Katie E Hebron, Elizabeth Y Li, Shanna A Arnold Egloff, Ariana K von Lersner, Chase Taylor, Joep Houkes, David K Flaherty, Adel Eskaros, Thomas P Stricker, Andries Zijlstra

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Katie E HebronVanderbilt University, Program in Cancer Biology, Nashville, USA.
Elizabeth Y LiDepartment of Biology, Massachusetts Institute of Technology, Cambridge, USA.
Shanna A Arnold EgloffDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, USA.
Ariana K von LersnerVanderbilt University, Program in Cancer Biology, Nashville, USA.
Chase TaylorDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, USA.
Joep HoukesDepartment of Microbiology, Wageningen University and Research, Wageningen, Netherlands.ORCID 0000-0002-7937-726X
David K FlahertyVanderbilt University Medical Center, Vanderbilt Vaccine Center, Nashville, USA.
Adel EskarosDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, USA.
Thomas P StrickerDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, USA.
Andries ZijlstraVanderbilt University, Program in Cancer Biology, Nashville, USA. Andries.Zijlstra@Vanderbilt.Edu.ORCID 0000-0001-8460-8803
Vanderbilt University · USVanderbilt University Medical Center · USVA Tennessee Valley Healthcare System · USMassachusetts Institute of Technology · USWageningen University & Research · NL

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
MULTIDISCIPLINARY BASIC RESEARCH TRAINING IN CANCERT32CA009592 · NCI · VANDERBILT UNIVERSITY · PI Justin M Balko, Julie A Rhoades (Sterling) · 1987 to 2026
$10.4M
Tetraspanin-mediated regulation of tumor cell migration and metastasisR01CA143081 · NCI · VANDERBILT UNIVERSITY · PI ZIJLSTRA, ANDRIES · 2010 to 2014
$1.5M
Regulation of prostate cancer progression by ALCAM proteolysisF31CA189764 · NCI · VANDERBILT UNIVERSITY · PI HEBRON, KATIE ELIZABETH · 2014 to 2016
$76k
ALCAM as a Biomarker of Treatment Response and Progression in Urogenital CancersIK2BX002498 · VA · VETERANS HEALTH ADMINISTRATION · PI ARNOLD, SHANNA ALEXANDRIA · 2015 to 2020
–
BLRD VA IK2 BX002498NCI NIH HHS F31 CA189764NCI NIH HHS P30 CA068485NCI NIH HHS R01 CA143081NCI NIH HHS T32 CA009592NIDDK NIH HHS P30 DK058404
6 · The paper itself

Abstract

While many adhesion receptors are known to influence tumor progression, the mechanisms by which they dynamically regulate cell-cell adhesion remain elusive. We previously identified Activated Leukocyte Cell Adhesion Molecule (ALCAM) as a clinically relevant driver of metastasis and hypothesized that a tunable mechanism of ectodomain shedding regulates its contribution to dissemination. To test this hypothesis, we examined an under-explored ALCAM splice variant (ALCAM-Iso2) and demonstrated that loss of the membrane-proximal region of ALCAM (exon 13) increased metastasis four-fold. Mechanistic studies identified a novel MMP14-dependent membrane distal cleavage site in ALCAM-Iso2, which mediated a ten-fold increase in shedding, thereby decreasing cellular cohesion. Importantly, the loss of cohesion is not limited to the cell capable of shedding because the released extracellular domain diminished cohesion of non-shedding cells through disruption of ALCAM-ALCAM interactions. ALCAM-Iso2-dominated expression in bladder cancer tissue, compared to normal bladder, further emphasizes that ALCAM alternative splicing may contribute to clinical disease progression. The requirement for both the loss of exon 13 and the gain of metalloprotease activity suggests that ALCAM shedding and concomitant regulation of tumor cell adhesion is a locally tunable process.

Indexed as

Alternative SplicingProteolysisActivated-Leukocyte Cell Adhesion MoleculeAnimalsCell AdhesionCell Line, TumorChick EmbryoChorioallantoic MembraneDisease ProgressionHumansMatrix Metalloproteinase 14Neoplasm MetastasisUrinary Bladder NeoplasmsActivated-Leukocyte Cell Adhesion MoleculeMatrix Metalloproteinase 14MMP14 protein, human

Identifiers

PMID29453336
PMCPMC5816644
OpenAlexW2797211534

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.